Status:
UNKNOWN
Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions
Lead Sponsor:
St. Joseph's Healthcare Hamilton
Collaborating Sponsors:
McMaster University
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Radiofrequency ablation (RFA) is an increasingly popular therapy option for treating small kidney cancer, especially for patients who are not ideal candidates for traditional surgery. Currently, follo...
Eligibility Criteria
Inclusion
- at least 18 years of age and capable of giving informed consent
- patient undergoing CT of MRI for monitoring of renal lesions after radiofrequency ablation
Exclusion
- pregnant patients
- patients with allergies to iodinated contrast agents
- patients with pulmonary hypertension, right-to-left cardiac shunts, or unstable cardiopulmonary disease (these are absolute or relative contraindications to the use of the ultrasound contrast agent, perflutren lipid microsphere)
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01141816
Start Date
January 1 2015
End Date
January 1 2022
Last Update
December 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Joseph's Healthcare
Hamilton, Ontario, Canada, L8N 4A6